^
    Back
    Association details:
    Biomarker:CD70 expression
    Cancer:Cutaneous T-cell Lymphoma
    Drug:cusatuzumab (ARGX-110) (CD70 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer
    Title:

    Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma

    Published date:
    11/02/2021
    Excerpt:
    The pharmacokinetics, immunogenicity, CD70 expression, and CD70/CD27 biology were also assessed....The overall response rate was 23%; this included 1 complete response and 5 partial responses (PRs) in 26 of the 27 evaluable patients. In addition, 9 patients achieved stable disease....Cusatuzumab was well tolerated, and antitumor activity was observed at both 1 and 5 mg/kg in highly pretreated patients with R/R CTCL.
    DOI:
    10.1002/cncr.34005